LDS/Medical Tests/Coagulation Factor II Activity Assay, Plasma

Coagulation Factor II Activity Assay, Plasma

Prothrombin (coagulation factor II) is a vitamin K–dependent serine protease synthesized in the liver and encoded by the F2 gene. During the coagulation cascade, prothrombin is cleaved to thrombin, a central enzyme responsible for converting fibrinogen to fibrin, activating platelets, and amplifying multiple steps of clot formation. Adequate prothrombin activity is therefore essential for normal hemostasis and wound repair.

Inherited prothrombin deficiency is a rare autosomal recessive bleeding disorder with an estimated prevalence of approximately 1 in 1–2 million individuals. Affected patients may be homozygous or compound heterozygous for pathogenic F2 variants and often present in infancy or childhood. Clinical manifestations range from mild mucocutaneous bleeding to severe hemorrhage, including hemarthroses, muscle hematomas, and excessive bleeding following surgery or trauma. The severity of bleeding does not always correlate directly with measured prothrombin activity levels, as some individuals with very low levels may exhibit mild symptoms, while others with moderately reduced levels experience severe bleeding.

Laboratory evaluation typically demonstrates a prolonged prothrombin time (PT) and a normal to mildly prolonged activated partial thromboplastin time (aPTT), with reduced factor II activity. Prothrombin deficiency can be subclassified into hypoprothrombinemia, characterized by reduced antigen and activity levels, dysprothrombinemia, in which antigen levels are normal but functional activity is reduced due to a dysfunctional molecule, and combined defects. Measurement of factor II activity is essential for identifying dysprothrombinemia and distinguishing inherited from acquired causes.

Acquired reductions in prothrombin activity are more common and may occur in liver disease, vitamin K deficiency, disseminated intravascular coagulation, and during anticoagulant therapy with vitamin K antagonists such as warfarin. Factor II is among the last vitamin K–dependent clotting factors to decrease after initiation of warfarin therapy and one of the last to normalize following discontinuation or reversal, often requiring 10 to 14 days to return to baseline. Management of bleeding due to prothrombin deficiency relies on replacement therapy, historically with fresh frozen plasma or prothrombin complex concentrates, and genetic testing of the F2 gene supports definitive diagnosis, subtype classification, and family counseling.

  • Aids in the diagnosis of congenital coagulation factor II (prothrombin) deficiency
  • Evaluation of acquired reductions in factor II activity associated with liver disease, vitamin K deficiency, oral anticoagulant therapy, and antibody-mediated deficiencies, including those related to lupus anticoagulant
  • Assessment and monitoring of warfarin therapy in patients with nonspecific coagulation inhibitors, where PT/INR alone may be unreliable
  • Determination of the degree of anticoagulation in patients receiving warfarin, particularly when correlation with other vitamin K–dependent proteins (e.g., protein S) when clinically indicated
  • Investigation of unexplained prolongation of prothrombin time (PT) and/or activated partial thromboplastin time (aPTT) as part of a comprehensive coagulation evaluation

Increased activity may be observed following vitamin K administration, during early reversal of warfarin therapy, or after transfusion with fresh frozen plasma.

Decreased activity is seen in liver disease, vitamin K deficiency, disseminated intravascular coagulation, hereditary prothrombin deficiency, and during warfarin therapy. Results should be interpreted in conjunction with PT/INR, aPTT, clinical findings, and other coagulation factor assays.

Adults: 75 - 145%

Neonates: 25 – 50%

Functional clot-based assay using prothrombin time (PT) with factor II–deficient substrate.

Platelet-poor plasma, sodium citrate (light-blue top tube), 5 mL. 

Patients should not be receiving warfarin or heparin at the time of collection unless monitoring therapy is the clinical indication. 

Stability

  • Ambient: 4 hours
  • Refrigerated: 24 hours
  • Frozen: 14 days
PT/ INR, aPTT, Factor V, VII, VIII, IX, X assays for comprehensive coagulation evaluation.
1 to 3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login